Keros Therapeutics, Inc. Operating Income
Keros Therapeutics, Inc. (KROS) reported Operating Income of -$30.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-03
- Keros Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$30.94M.
- Keros Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$25.88M, a 117.02% decline year-over-year.
- Keros Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$29.27M.
- Keros Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$15.38M.
- Keros Therapeutics, Inc. operating income (loss) for fiscal 2025 was $67.57M.
- Keros Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$210.83M.
- Keros Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$169.94M.
- Keros Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$114.79M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$30.94M 10-Q · filed 2026-08-03 | -$56.81M 10-Q · filed 2026-08-03 | -$86.08M derived: sum of 3 quarters · filed 2026-08-03 | -$101.47M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$25.88M 10-Q · filed 2026-05-14 | -$55.15M derived: sum of 2 quarters · filed 2026-05-14 | -$70.53M derived: sum of 3 quarters · filed 2026-05-14 | -$110.35M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$29.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$44.65M derived: sum of 2 quarters · filed 2026-03-04 | -$84.47M derived: sum of 3 quarters · filed 2026-08-03 | $67.57M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$15.38M 10-Q · filed 2025-11-05 | -$55.20M derived: sum of 2 quarters · filed 2026-08-03 | $96.84M 10-Q · filed 2025-11-05 | $43.59M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$39.82M 10-Q · filed 2026-08-03 | $112.22M 10-Q · filed 2026-08-03 | $58.97M derived: sum of 3 quarters · filed 2026-08-03 | $312.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $152.04M 10-Q · filed 2026-05-14 | $98.79M derived: sum of 2 quarters · filed 2026-05-14 | $40.13M derived: sum of 3 quarters · filed 2026-05-14 | -$10.31M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$53.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$111.91M derived: sum of 2 quarters · filed 2026-03-04 | -$162.35M derived: sum of 3 quarters · filed 2026-03-04 | -$210.83M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$58.66M 10-Q · filed 2025-11-05 | -$109.10M derived: sum of 2 quarters · filed 2025-11-05 | -$157.58M 10-Q · filed 2025-11-05 | -$204.03M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$50.44M 10-Q · filed 2025-08-06 | -$98.92M 10-Q · filed 2025-08-06 | -$145.38M derived: sum of 3 quarters · filed 2025-08-06 | -$188.66M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$48.48M 10-Q · filed 2025-05-06 | -$94.94M derived: sum of 2 quarters · filed 2025-05-06 | -$138.22M derived: sum of 3 quarters · filed 2025-05-06 | -$179.56M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$46.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$89.73M derived: sum of 2 quarters · filed 2025-02-26 | -$131.07M derived: sum of 3 quarters · filed 2025-02-26 | -$169.94M 10-K · filed 2025-02-26 |
| 2023-09-30 | -$43.28M 10-Q · filed 2024-11-06 | -$84.62M derived: sum of 2 quarters · filed 2024-11-06 | -$123.49M 10-Q · filed 2024-11-06 | -$155.45M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$41.34M 10-Q · filed 2024-08-07 | -$80.21M 10-Q · filed 2024-08-07 | -$112.17M derived: sum of 3 quarters · filed 2025-02-26 | -$140.14M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$38.87M 10-Q · filed 2024-05-08 | -$70.83M derived: sum of 2 quarters · filed 2025-02-26 | -$98.81M derived: sum of 3 quarters · filed 2025-02-26 | -$129.53M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$31.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$59.94M derived: sum of 2 quarters · filed 2025-02-26 | -$90.66M derived: sum of 3 quarters · filed 2025-02-26 | -$114.79M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$27.98M 10-Q · filed 2023-11-06 | -$58.70M derived: sum of 2 quarters · filed 2023-11-06 | -$82.83M 10-Q · filed 2023-11-06 | -$87.70M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$30.73M 10-Q · filed 2023-08-07 | -$54.85M 10-Q · filed 2023-08-07 | -$59.72M derived: sum of 3 quarters · filed 2024-02-28 | -$79.92M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$24.13M 10-Q · filed 2023-05-04 | -$28.99M derived: sum of 2 quarters · filed 2024-02-28 | -$49.19M derived: sum of 3 quarters · filed 2024-02-28 | -$64.73M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$4.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$25.06M derived: sum of 2 quarters · filed 2024-02-28 | -$40.60M derived: sum of 3 quarters · filed 2024-02-28 | -$56.37M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$20.20M 10-Q · filed 2022-11-03 | -$35.74M derived: sum of 2 quarters · filed 2022-11-03 | -$51.51M 10-Q · filed 2022-11-03 | -$64.80M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$15.54M 10-Q · filed 2022-08-04 | -$31.31M 10-Q · filed 2022-08-04 | -$44.60M derived: sum of 3 quarters · filed 2022-08-04 | -$56.55M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$15.77M 10-Q · filed 2022-05-05 | -$29.06M derived: sum of 2 quarters · filed 2022-05-05 | -$41.01M derived: sum of 3 quarters · filed 2022-05-05 | -$51.92M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$13.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$25.24M derived: sum of 2 quarters · filed 2022-03-09 | -$36.15M derived: sum of 3 quarters · filed 2022-03-09 | -$46.66M 10-K · filed 2022-03-09 |
| 2020-09-30 | -$11.95M 10-Q · filed 2021-11-04 | -$22.86M derived: sum of 2 quarters · filed 2021-11-04 | -$33.37M 10-Q · filed 2021-11-04 | -$36.09M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$10.91M 10-Q · filed 2021-08-05 | -$21.42M 10-Q · filed 2021-08-05 | -$24.15M derived: sum of 3 quarters · filed 2021-08-05 | -$26.47M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$10.50M 10-Q · filed 2021-05-06 | -$13.23M derived: sum of 2 quarters · filed 2021-05-06 | -$15.56M derived: sum of 3 quarters · filed 2021-05-06 | -$18.21M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$5.05M derived: sum of 2 quarters · filed 2021-03-25 | -$7.71M derived: sum of 3 quarters · filed 2021-03-25 | -$10.56M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$2.33M 10-Q · filed 2020-11-10 | -$4.98M derived: sum of 2 quarters · filed 2020-11-10 | -$7.83M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$2.65M 10-Q · filed 2020-08-13 | -$5.51M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | -$2.86M 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |